Salvati L.; Palterer B.; Lazzeri E.; Vivarelli E.; Amendola M.; Allinovi M.; Caroti L.; Mazzoni A.; Lasagni L.; Emmi G.; Cavigli E.; Del Carria M.; Di Pietro L.; Scavone M.; Cammelli D.; Lavorini F.; Tomassetti S.; Rosi E.; Parronchi P. (2024). Presentation and progression of MPO-ANCA interstitial lung disease. JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, vol. 8, pp. 0-0, ISSN:2589-9090 DOI  

  Nencini F.; Vultaggio A.; Pratesi S.; Cammelli D.; Milla M.; Fiori G.; Bagnoli S.; Prignano F.; Romagnani S.; Maggi E.; Matucci A. (2018). The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. IN PRACTICE, vol. 6, pp. 2065-2072.e2, ISSN:2213-2198 DOI  

  Vultaggio A.; Petroni G.; Pratesi S.; Nencini F.; Cammelli D.; Milla M.; Prignano F.; Annese V.; Romagnani S.; Maggi E.; Matucci A. (2016). Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 186, pp. 364-372, ISSN:0009-9104 DOI